Just something to think about or discuss I am still of the belief that we cannot fail to be successful. I asked chatGPT the following question. Do any scenarios apply to us.
Question
"Have there been any examples of the best drug for a particular disease failing as a financially successful product"
AnswerYes, there have been multiple examples where a drug that was considered highly effective for a particular disease failed commercially. This can happen due to pricing, competition, marketing, access issues, or strategic missteps. Here are some notable examples:
1. Dendreon’s Provenge (Sipuleucel-T)
- Disease: Prostate cancer
- Effectiveness: Provenge was the first FDA-approved cancer vaccine (2010) and showed a survival benefit in men with metastatic prostate cancer.
- Why it failed financially:
- Very high cost (~$93,000 for a full course)
- Complex logistics (personalized therapy requiring leukapheresis and processing)
- Slow adoption by physicians
- Company eventually filed for bankruptcy in 2014 despite medical success.
2. Pfizer’s Exubera
- Disease: Diabetes (inhaled insulin)
- Effectiveness: Worked well as an alternative to injected insulin, especially for needle-phobic patients
- Why it failed financially:
- Bulky delivery device, impractical for daily use
- Poor marketing and lack of physician enthusiasm
- High cost compared to traditional insulin
- Pulled from the market in 2007, just one year after launch
- Pfizer took a $2.8 billion write-off
3. Roche’s Viracept (Nelfinavir)
- Disease: HIV/AIDS
- Effectiveness: Once a mainstay in HIV treatment regimens
- Why it lost traction:
- Contamination scare in 2007 led to recalls and a tarnished image
- Emergence of newer antiretrovirals with better tolerability and fewer pills
- Despite being effective, it lost market share quickly
4. Biogen’s Aduhelm (Aducanumab)
- Disease: Alzheimer’s disease
- Effectiveness: First Alzheimer’s drug to target amyloid plaques, but with very mixed evidence of clinical benefit
- Why it flopped financially (so far):
- Massive backlash over FDA approval process
- CMS (Medicare) severely limited coverage
- Very high price ($56,000/year initially)
- Doctors hesitant to prescribe due to doubts about benefit and MRI monitoring burden
- Despite being the only approved disease-modifying treatment, sales were extremely poor
5. Zyvox (Linezolid) by Pharmacia/Pfizer
- Disease: Gram-positive bacterial infections (like MRSA)
- Effectiveness: Highly effective oral antibiotic for resistant infections
- Why not a blockbuster:
- Reserved for hospital use due to cost and to prevent resistance
- Limited duration of treatment
- Antibiotics are not usually high earners due to short-term use and stewardship policies
Key Reasons Why Good Drugs Fail Commercially:
- Pricing mismatch with payer willingness
- Logistical challenges or delivery method issues
- Regulatory or perception problems
- Fierce competition or rapid obsolescence
- Poor strategic execution (marketing, education, access)
Let me know if you want case studies specific to a therapeutic area (e.g., oncology, infectious disease, psychiatry).
- Forums
- ASX - By Stock
- BOT - Anything but charting
BOT
botanix pharmaceuticals ltd
Add to My Watchlist
8.62%
!
31.5¢

Just something to think about or discuss I am still of the...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
31.5¢ |
Change
0.025(8.62%) |
Mkt cap ! $617.6M |
Open | High | Low | Value | Volume |
30.0¢ | 32.5¢ | 29.5¢ | $3.773M | 12.14M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 105056 | 31.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
31.5¢ | 29998 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 105056 | 0.310 |
14 | 575211 | 0.305 |
22 | 1512848 | 0.300 |
12 | 701504 | 0.295 |
22 | 893421 | 0.290 |
Price($) | Vol. | No. |
---|---|---|
0.315 | 29998 | 1 |
0.320 | 398549 | 2 |
0.325 | 313230 | 4 |
0.330 | 172449 | 5 |
0.335 | 480114 | 5 |
Last trade - 16.10pm 26/06/2025 (20 minute delay) ? |
Featured News
BOT (ASX) Chart |
The Watchlist
PTX
PRESCIENT THERAPEUTICS LIMITED
James McDonnell, CEO
James McDonnell
CEO
Previous Video
Next Video
SPONSORED BY The Market Online